Secondary analysis of 792 children and adolescents with HIV: at week 240 (cohort ≥14 kg), weight gain did not differ significantly on dolutegravir-based ART vs standard of care (+1.0 kg, p=0.095); total cholesterol, triglycerides and glucose were lower with dolutegravir.
Secondary analysisn = 792
Turkova et al. Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial